Portal de Periódicos da CAPES

Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects

2004; Cambridge University Press; Volume: 91; Issue: 3 Linguagem: Inglês

10.1079/bjn20031064

1475-2662

Erik Näslund, Neil A. King, S. Mansten, N. Adner, Jens J. Holst, M. Gutniak, Per M. Hellström,

Regulation of Appetite and Obesity

Recombinant glucagon-like peptide-1 (7–36)amide (rGLP-1) was recently shown to cause significant weight loss in type 2 diabetics when administered for 6 weeks as a continuous subcutaneous infusion. The mechanisms responsible for the weight loss are not clarified. In the present study, rGLP-1 was given for 5d by prandial subcutaneous injections (PSI) (76nmol 30min before meals, four times daily; a total of 302·4nmol/24h) or by continuous subcutaneous infusion (CSI) (12·7nmol/h; a total of 304·8nmol/24h). This was performed in nineteen healthy obese subjects (mean age 44·2 (sem 2·5) years; BMI 39·0 (sem 1·2)kg/m 2 ) in a prospective randomised, double-blind, placebo-controlled, cross-over study. Compared with the placebo, rGLP-1 administered as PSI and by CSI generated a 15% reduction in mean food intake per meal ( P =0·02) after 5d treatment. A weight loss of 0·55 (sem 0·2) kg ( P <0·05) was registered after 5d with PSI of rGLP-1. Gastric emptying rate was reduced during both PSI ( P <0·001) and CSI ( P <0·05) treatment, but more rapidly and to a greater extent with PSI of rGLP-1. To conclude, a 5d treatment of rGLP-1 at high doses by PSI, but not CSI, promptly slowed gastric emptying as a probable mechanism of action of increased satiety, decreased hunger and, hence, reduced food intake with an ensuing weight loss.